Regulatory Services
FDA's labeling and advertising requirements for cleared and approved medical devices are not self-enforcing — they require active review of promotional materials, website content, and sales claims. Off-label promotion is the most common labeling enforcement action FDA takes against device manufacturers, and it most often occurs because marketing communications weren't reviewed before release.
Review Your Promotional MaterialsAdvertising Compliance
A medical device that is promoted for a use not included in its FDA clearance or approval is considered misbranded under Section 502 of the FD&C Act. Promotional communications — whether brochures, website content, sales training materials, conference presentations, or social media — that imply clinical uses beyond the cleared indication expose the manufacturer to FDA enforcement action, including warning letters, injunctions, seizures, and in some cases criminal penalties. Unlike pharmaceutical off-label promotion, device labeling and advertising issues are enforced primarily through FDA's inspection program and complaint-based enforcement, but FDA's Office of Regulatory Affairs actively monitors medical device promotional materials for compliance.
The most common off-label promotion patterns we identify in promotional material reviews are: claims that imply efficacy in specific clinical conditions not included in the indication for use, comparative claims against competitor devices without adequate substantiation, claims drawn from clinical studies that don't match the cleared intended use population, and website copy written without reference to the FDA-cleared indication. The line between legitimate product promotion and unlawful off-label promotion requires regulatory judgment — marketing teams without regulatory oversight routinely cross it without intending to.
A promotional material review evaluates each claim in a piece of promotional content against the cleared or approved indication for use, any applicable special controls or post-market commitments, and FDA's policies on comparative claims and clinical evidence references. The review output identifies claims that require modification, claims that require substantiation documentation, and claims that cannot be made under any circumstances for the cleared device. For claims supported by clinical data, we assess whether the cited data actually supports the claim as made — not just whether the data exists.
We review promotional materials across all channels: product brochures, packaging, websites, digital advertising, sales training materials, conference presentations, and scientific publications used in a promotional context. Physician testimonials and case studies require specific compliance analysis — FDA's requirements for testimonial advertising differ from consumer-directed advertising, and the context in which case studies are used matters for regulatory classification as promotion.
The most effective labeling and advertising compliance program is not a reactive review after materials are created — it is a pre-release review process built into the marketing workflow. We design promotional material review SOPs that specify the regulatory review requirements for each type of material, the substantiation documentation that must be on file before a claim is used, and the escalation path for borderline claims. Companies with functioning promotional review processes identify and correct compliance issues before materials reach physicians or patients — not after an FDA investigator has identified them during an inspection or complaint investigation.
Get Started
Marketing teams work fast and don't always see regulatory boundaries. We build the review processes and provide the expert oversight that keeps promotional content compliant with FDA's labeling and advertising requirements.